Beta Drugs Ltd

NSE: BETA · BSE: 531481 · Pharmaceuticals & Biotechnology · 27 announcements

Share price: ₹1,981.10
Market cap: ₹2,196 Cr
Revenue (annual): ₹384.8 Cr
Net profit (annual): ₹41.48 Cr
P/E (TTM): 48.2×Sector 47.4×
Promoter holding: 59.10%-5.53% QoQ
FII holding: 1.02%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

22 Apr 2026 09:00 IST NSE

Beta Drugs Regulatory Approval

Beta Drugs Limited achieved regulatory milestones in Azerbaijan and the Philippines. The company received generic drug approvals for two brands in the Philippines and successfully completed an Azerbaijan Ministry of Health inspection. These developments enhance access to CIS and Southeast Asian markets, supporting future export revenue growth.

Execution: Expected GMP approval in 1-2 months; further Philippines approvals in 6 months

Read the filing ↗